Skip to content

The effect of tegretol on nausea and vomiting after gynecological laparoscopic surgery for postoperative analgesia: A single-center, prospective, randomized controlled clinical trial

The effect of tegretol on nausea and vomiting after gynecological laparoscopic surgery for postoperative analgesia: A single-center, prospective, randomized controlled clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107859
Enrollment
Unknown
Registered
2025-08-20
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative nausea and vomiting after gynecological surgery

Interventions

The teglitazone treatment group:Loading dose: 0.75 mg / 5 ml, administered by pump for 10 minutes
Maintenance: Prepared as 0.05 mg/ml, add 0.05 mg of dose with each press, add 1 ml of volume, and lock the dose for 10 minutes with each press.
The morphine treatment group:Loading dose: 3.0 mg / 5 ml, administered by pump for 10 minutes
Maintenance: Prepared as 1 mg/ml, add 1 mg of dose with each press, add 1 ml of volume, and lock the dose for 10 minutes with each press

Sponsors

Affiliated Hospital of Qingdao University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Age: 18 - 80 years old; 2.ASA classification: 1 - 3 grades; 3.Scheduled for elective gynecological laparoscopic surgery under general anesthesia; 4.Within 4 hours after the surgery, at any time, the resting NRS score was = 4 points; 5. Signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Allergic to selective µ-receptor agonists or having taken such drugs within one week before the surgery; 2. Long-term use of long-acting antiemetic drugs, emetic drugs, opioid drugs or glucocorticoids, etc.; 3. Pregnant or lactating women; 4. Patients with developmental delay, mental disorders or severe neurological diseases; 5. Other diseases that may cause nausea and vomiting, such as hepatitis or gastric ulcers; 6. Refusal to participate in this clinical trial; 7. Allergic or having contraindications to the anesthetics, adjuvant analgesics, rescue analgesics, antiemetics, and antibiotics used in the study.

Design outcomes

Primary

MeasureTime frame
The incidence of nausea and vomiting 24 hours after the operation;

Secondary

MeasureTime frame
The NRS score for pain 24 hours after the operation;Quality of recovery;

Countries

China

Contacts

Public ContactXiaojie Liu

Affiliated Hospital of Qingdao University

mmliuxiaojie@163.com+86 185 6185 7226

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026